. 2007 Jun 21;13(23):3206–3214. doi: 10.3748/wjg.v13.i23.3206

Table 3.

Gastrointestinal symptom score for 21 apparently healthy controls and for 21 IBS patients at 0, 12 and 24 wk of treatment and 6 mo after end of treatment

Category	Before treatment		After 12 wk		After 24 wk		6 mo after end of treatment
	M	Md (IQR)	M	Md (IQR)	M	Md (IQR)	M	Md (IQR)
AHC group
Totally	0.4	0 (1)^d
Pain	0.4	0 (1)^d
Flatulence	0.4	0 (1)^d
Nausea	0.2	0 (1)
Constipation	0.6	0 (1)^b
Diarrhoea	0.3	0 (1)^d
Motility	0.5	0 (1)^d
Other	0.3	1 (0)^d

IBS patients
Totally	1.8	1 (3)	1.6	1 (3)^d	1.3	1 (2)^d	1.4	1 (2)^d
Pain	1.9	2 (2)	1.9	2 (3)	1.5	2 (2)^d	1.4	1 (2)^d
Flatulence	2.5	2 (3)	2.2	2 (2)^b	1.8	2 (2)^d	2.0	2 (2)^b
Nausea	1.4	1 (2)	1.0	0 (2)^a	0.9	0 (2)^a	0.8	0 (1)^a
Constipation	1.9	2 (3)	1.5	1 (2)^a	1.1	1 (2)^b	1.4	1 (2)^a
Diarrhoea	1.9	1 (3)	1.6	2 (1)	1.2	1 (2)^d	1.2	1 (2)^b
Motility	2.6	2 (3)	2.2	2 (2)^a	1.9	2 (1)^a	2.1	2 (2)
Others	1.2	1 (1)	1.2	1 (1)	1.1	1 (1)^a	1.1	0 (1)^a

The result is shown totally and categorized. The higher score the more symptoms. M denotes mean, MD: median; IQR: inter quartile range; AHC: apparently healthy controls.

P < 0.05,

P < 0.01,

P < 0.001 vs IBS patients at 0 wk.